U.S. Markets closed
  • S&P 500

    3,435.56
    -7.56 (-0.22%)
     
  • Dow 30

    28,210.82
    -97.97 (-0.35%)
     
  • Nasdaq

    11,484.69
    -31.80 (-0.28%)
     
  • Russell 2000

    1,603.78
    -13.93 (-0.86%)
     
  • Crude Oil

    39.97
    -1.73 (-4.15%)
     
  • Gold

    1,927.40
    +12.00 (+0.63%)
     
  • Silver

    25.15
    +0.17 (+0.68%)
     
  • EUR/USD

    1.1862
    +0.0034 (+0.2847%)
     
  • 10-Yr Bond

    0.8160
    +0.0190 (+2.38%)
     
  • Vix

    28.65
    -0.70 (-2.39%)
     
  • GBP/USD

    1.3139
    +0.0192 (+1.4820%)
     
  • USD/JPY

    104.5730
    -0.8970 (-0.8505%)
     
  • BTC-USD

    12,733.67
    +1,676.66 (+15.16%)
     
  • CMC Crypto 200

    255.21
    +10.32 (+4.21%)
     
  • FTSE 100

    5,776.50
    -112.72 (-1.91%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NNOX, ODT and GOCO

·3 mins read

NEW YORK, NY / ACCESSWIRE / September 25, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Nano-X Imaging Ltd. (NASDAQ:NNOX)
Class Period: August 21, 2020 - September 15, 2020
Lead Plaintiff Deadline: November 16, 2020

The NNOX lawsuit alleges that throughout the class period, Nano-X Imaging Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) Nano-X's commercial agreements and its customers were fabricated; (2) Nano-X's statements regarding its "novel" Nanox System were misleading as the Company never provided data comparing its images with images from competitors' machines; (3) Nano-X's submission to the U.S. Food and Drug Administration admitted the Nanox System was not original; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Learn about your recoverable losses in NNOX: http://www.kleinstocklaw.com/pslra-1/nano-x-imaging-ltd-loss-submission-form?id=9616&from=1

Odonate Therapeutics, Inc. (NASDAQ:ODT)
Class Period: December 7, 2017 - April 21, 2020
Lead Plaintiff Deadline: November 16, 2020

Throughout the class period, Odonate Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel's commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ODT: http://www.kleinstocklaw.com/pslra-1/odonate-therapeutics-inc-loss-submission-form?id=9616&from=1

GoHealth, Inc. (NASDAQ:GOCO)
The GoHealth lawsuit is on behalf of all purchasers of GoHealth Class A common stock pursuant and/or traceable to the registration statement issued in connection with GoHealth's July 2020 initial public offering.
Lead Plaintiff Deadline: November 20, 2020

The GOCO lawsuit alleges GoHealth, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020; (ii) GoHealth suffered from a higher risk of customer churn as a result of its unique business model and limited carrier base; (iii) GoHealth suffered from degradations in customer persistency and retention as a result of elevated industry churn, vulnerabilities that arose from the Company's concentrated carrier business model, and GoHealth's efforts to expand into new geographies, develop new carrier partnerships and worsening product mix; (iv) GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and (v) these adverse financial and operational trends were internally projected by GoHealth to continue and worsen following the initial public offering.

Learn about your recoverable losses in GOCO: http://www.kleinstocklaw.com/pslra-1/gohealth-inc-loss-submission-form?id=9616&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/607855/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-NNOX-ODT-and-GOCO